Imunon, Inc. Net Income (Loss) Available to Common Stockholders, Basic
Imunon, Inc. (IMNN) reported Net Income (Loss) Available to Common Stockholders, Basic of -$2.83 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic · last filed 2026-08-11
- Imunon, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2026-06-30 was -$2.83M.
- Imunon, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2025-06-30 was -$2.74M.
- Imunon, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2018-12-31 was $5.48M.
- Imunon, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2018-09-30 was -$4.66M.
- Imunon, Inc. net income (loss) available to common stockholders, basic for fiscal 2018 was -$11.88M.
- Imunon, Inc. net income (loss) available to common stockholders, basic for fiscal 2017 was -$20.75M.
- Imunon, Inc. net income (loss) available to common stockholders, basic for fiscal 2016 was -$22.05M.
- Imunon, Inc. net income (loss) available to common stockholders, basic for fiscal 2015 was -$22.46M.
| Period end | Net Income (Loss) Available to Common Stockholders, Basic 3 month | Net Income (Loss) Available to Common Stockholders, Basic 3 month as first filed | Net Income (Loss) Available to Common Stockholders, Basic 6 month | Net Income (Loss) Available to Common Stockholders, Basic 9 month | Net Income (Loss) Available to Common Stockholders, Basic 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | -$2.83M 10-Q · filed 2026-08-11 | -$7.08M 10-Q · filed 2026-08-11 | |||
| 2025-06-30 | -$2.74M 10-Q · filed 2026-08-11 | -$6.84M 10-Q · filed 2026-08-11 | |||
| 2018-12-31 | $5.48M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-29 | $824.19K derived: sum of 2 quarters · filed 2019-03-29 | -$7.41M derived: sum of 3 quarters · filed 2019-03-29 | -$11.88M 10-K · filed 2019-03-29 | |
| 2018-09-30 | -$4.66M 10-Q · filed 2018-11-14 | -$12.89M derived: sum of 2 quarters · filed 2018-11-14 | -$17.36M 10-Q · filed 2018-11-14 | -$22.04M derived: sum of 4 quarters · filed 2019-03-29 | |
| 2018-06-30 | -$8.23M 10-Q · filed 2018-08-14 | -$12.71M 10-Q · filed 2018-08-14 | -$17.39M derived: sum of 3 quarters · filed 2019-03-29 | -$23.06M derived: sum of 4 quarters · filed 2019-03-29 | |
| 2018-03-31 | -$4.48M derived: 10-K 12 month − 3 quarters · filed 2019-03-29 | -$9.16M derived: sum of 2 quarters · filed 2019-03-29 | -$14.83M derived: sum of 3 quarters · filed 2019-03-29 | -$20.50M derived: sum of 4 quarters · filed 2019-03-29 | |
| 2017-12-31 | -$4.68M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-29 | -$10.35M derived: sum of 2 quarters · filed 2019-03-29 | -$16.02M derived: sum of 3 quarters · filed 2019-03-29 | -$20.75M 10-K · filed 2019-03-29 | |
| 2017-09-30 | -$5.67M 10-Q · filed 2017-11-14 | -$11.34M derived: sum of 2 quarters · filed 2018-11-14 | -$16.07M 10-Q · filed 2018-11-14 | -$21.90M derived: sum of 4 quarters · filed 2018-11-14 | |
| 2017-06-30 | -$5.67M 10-Q · filed 2018-11-14 | -$5.24M 10-Q · filed 2017-08-14 | -$10.40M 10-Q · filed 2018-08-14 | -$16.23M derived: sum of 3 quarters · filed 2018-11-14 | -$22.64M derived: sum of 4 quarters · filed 2018-11-14 |
| 2017-03-31 | -$5.16M 10-Q · filed 2017-05-12 | -$10.56M derived: sum of 2 quarters · filed 2018-03-27 | -$16.97M derived: sum of 3 quarters · filed 2018-03-27 | -$21.50M derived: sum of 4 quarters · filed 2018-03-27 | |
| 2016-12-31 | -$5.40M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-27 | -$11.81M derived: sum of 2 quarters · filed 2018-03-27 | -$16.34M derived: sum of 3 quarters · filed 2018-03-27 | -$22.05M 10-K · filed 2018-03-27 | |
| 2016-09-30 | -$6.41M 10-Q · filed 2017-11-14 | -$10.94M derived: sum of 2 quarters · filed 2017-11-14 | -$16.66M 10-Q · filed 2017-11-14 | -$22.17M derived: sum of 4 quarters · filed 2017-11-14 | |
| 2016-06-30 | -$4.53M 10-Q · filed 2017-08-14 | -$10.25M 10-Q · filed 2017-08-14 | -$15.76M derived: sum of 3 quarters · filed 2017-08-14 | -$20.03M derived: sum of 4 quarters · filed 2017-08-14 | |
| 2016-03-31 | -$5.72M 10-Q · filed 2017-05-12 | -$11.23M derived: sum of 2 quarters · filed 2017-05-12 | -$15.50M derived: sum of 3 quarters · filed 2017-05-12 | -$21.17M derived: sum of 4 quarters · filed 2017-05-12 | |
| 2015-12-31 | -$5.51M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-24 | -$9.78M derived: sum of 2 quarters · filed 2017-03-24 | -$15.46M derived: sum of 3 quarters · filed 2017-03-24 | -$22.46M 10-K · filed 2017-03-24 | |
| 2015-09-30 | -$4.27M 10-Q · filed 2016-11-10 | -$9.94M derived: sum of 2 quarters · filed 2016-11-10 | -$16.95M 10-Q · filed 2016-11-10 | -$23.40M derived: sum of 4 quarters · filed 2016-11-10 | |
| 2015-06-30 | -$5.67M 10-Q · filed 2016-08-15 | -$12.68M 10-Q · filed 2016-08-15 | -$19.14M derived: sum of 3 quarters · filed 2016-08-15 | -$26.08M derived: sum of 4 quarters · filed 2016-08-15 | |
| 2015-03-31 | -$7.01M 10-Q · filed 2016-05-16 | -$13.46M derived: sum of 2 quarters · filed 2016-05-16 | -$20.40M derived: sum of 3 quarters · filed 2016-05-16 | -$27.08M derived: sum of 4 quarters · filed 2016-05-16 | |
| 2014-12-31 | -$6.46M derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-30 | -$13.40M derived: sum of 2 quarters · filed 2016-03-30 | -$20.07M derived: sum of 3 quarters · filed 2016-03-30 | -$25.49M 10-K · filed 2016-03-30 | |
| 2014-09-30 | -$6.94M 10-Q · filed 2015-11-05 | -$13.62M derived: sum of 2 quarters · filed 2015-11-05 | -$19.04M 10-Q · filed 2015-11-05 | -$22.99M derived: sum of 4 quarters · filed 2016-03-30 | |
| 2014-06-30 | -$6.67M 10-Q · filed 2015-08-10 | -$12.10M 10-Q · filed 2015-08-10 | -$16.05M derived: sum of 3 quarters · filed 2016-03-30 | -$20.12M derived: sum of 4 quarters · filed 2016-03-30 | |
| 2014-03-31 | -$5.42M 10-Q · filed 2015-05-11 | -$9.37M derived: sum of 2 quarters · filed 2016-03-30 | -$13.44M derived: sum of 3 quarters · filed 2016-03-30 | -$13.02M derived: sum of 4 quarters · filed 2016-03-30 | |
| 2013-12-31 | -$3.95M derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-30 | -$8.02M derived: sum of 2 quarters · filed 2016-03-30 | -$7.60M derived: sum of 3 quarters · filed 2016-03-30 | -$12.85M 10-K · filed 2016-03-30 | |
| 2013-09-30 | -$4.07M 10-Q · filed 2014-11-10 | -$3.65M derived: sum of 2 quarters · filed 2014-11-10 | -$8.90M 10-Q · filed 2014-11-10 | -$17.16M derived: sum of 4 quarters · filed 2015-03-12 | |
| 2013-06-30 | $420.88K 10-Q · filed 2014-08-07 | -$4.83M 10-Q · filed 2014-08-07 | -$13.09M derived: sum of 3 quarters · filed 2015-03-12 | -$19.11M derived: sum of 4 quarters · filed 2015-03-12 | |
| 2013-03-31 | -$5.25M 10-Q · filed 2014-05-08 | -$13.51M derived: sum of 2 quarters · filed 2015-03-12 | -$19.53M derived: sum of 3 quarters · filed 2015-03-12 | -$25.63M derived: sum of 4 quarters · filed 2015-03-12 | |
| 2012-12-31 | -$8.26M derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-12 | -$14.28M derived: sum of 2 quarters · filed 2015-03-12 | -$20.38M derived: sum of 3 quarters · filed 2015-03-12 | -$26.57M 10-K · filed 2015-03-12 | |
| 2012-09-30 | -$6.02M 10-Q · filed 2013-11-12 | -$12.12M derived: sum of 2 quarters · filed 2013-11-12 | -$18.31M 10-Q · filed 2013-11-12 | ||
| 2012-06-30 | -$6.10M 10-Q · filed 2013-08-08 | -$12.29M 10-Q · filed 2013-08-08 | |||
| 2012-03-31 | -$6.19M 10-Q · filed 2013-05-09 | ||||
| 2011-12-31 | -$23.22M 10-K · filed 2014-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |